A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ACHN-975 in Healthy Volunteers

A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of Intravenous (IV) ACHN-975 in Normal Healthy Volunteers

This is a double-blind, randomized, placebo-controlled, single ascending dose study to assess the safety, tolerability, and PK of ACHN-975 in normal healthy volunteers. This study will take place in the US at one clinical site.

Key Inclusion Criteria:

• Body weight between 40 and 100 kilograms (between ~88 pounds and ~220 pounds)
• Use of contraception
• Stable health
• Negative tests for alcohol, tobacco, and drugs of abuse

Key Exclusion Criteria:

• History of clinically significant disease
• Pregnancy